Exact Mass: 369.0857

Exact Mass Matches: 369.0857

Found 60 metabolites which its exact mass value is equals to given mass value 369.0857, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

S-(2-Chloroethyl)glutathione

S-(2-Chloroethyl)glutathione

C12H20ClN3O6S (369.0761)


   

lansoprazole

2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole

C16H14F3N3O2S (369.0759)


A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3137 Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

   

Lansoprazole

2-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl}-1H-1,3-benzodiazole

C16H14F3N3O2S (369.0759)


Lansoprazole is a proton pump inhibitor similar to omeprazole which prevents the stomach from producing acid. Lansoprazoles plasma elimination half-life is not proportional to the duration of the drugs effects (i.e. gastric acid suppression). The plasma elimination half-life is 1.5 hours or less, and the effects of the drug last for over 24 hours after it has been given for 5 days or more. [HMDB] Lansoprazole is a proton pump inhibitor similar to omeprazole which prevents the stomach from producing acid. Lansoprazoles plasma elimination half-life is not proportional to the duration of the drugs effects (i.e. gastric acid suppression). The plasma elimination half-life is 1.5 hours or less, and the effects of the drug last for over 24 hours after it has been given for 5 days or more. A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

   

Tripamide

N-[(1R,2S,6R)-4-Azatricyclo[5.2.1.0²,⁶]decan-4-yl]-4-chloro-3-sulphamoylbenzene-1-carboximidic acid

C16H20ClN3O3S (369.0914)


Tripamide belongs to the family of Aromatic Monoterpenes. These are monoterpenes containing at least one aromatic ring. D045283 - Natriuretic Agents > D004232 - Diuretics > D049994 - Sodium Potassium Chloride Symporter Inhibitors D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators

   

6-Hydroxy-R-acenocoumarol

4,6-dihydroxy-3-[(1S)-1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one

C19H15NO7 (369.0848)


6-Hydroxy-R-acenocoumarol is a metabolite of acenocoumarol. Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist. It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome. (Wikipedia)

   

7-Hydroxy-R-acenocoumarol

4,7-dihydroxy-3-[(1S)-1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one

C19H15NO7 (369.0848)


7-Hydroxy-R-acenocoumarol is a metabolite of acenocoumarol. Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist. It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome. (Wikipedia)

   

8-Hydroxy-R-acenocoumarol

4,8-dihydroxy-3-[(1S)-1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one

C19H15NO7 (369.0848)


8-Hydroxy-R-acenocoumarol is a metabolite of acenocoumarol. Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist. It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome. (Wikipedia)

   

Chloro-{methyl-[1-(2-methyl-5,6-dihydro-[1,4]oxathiin-3-yl)-methanoyl]-amino}-benzoic acid, isopropyl ester

Chloro-{methyl-[1-(2-methyl-5,6-dihydro-[1,4]oxathiin-3-yl)-methanoyl]-amino}-benzoic acid, isopropyl ester

C17H20ClNO4S (369.0802)


   

Chaetoquadrin D

Chaetoquadrin D

C16H19NO7S (369.0882)


   

N-[3-(aminosulfonyl)phenyl]-2-phenoxynicotinamide

N-[3-(aminosulfonyl)phenyl]-2-phenoxynicotinamide

C18H15N3O4S (369.0783)


   
   

Drahebephin A

Drahebephin A

C19H15NO7 (369.0848)


   

((4,5-dichloro-1H-pyrrol-2-yl)-[2,4-dihydroxy-3-((S)-4-methylhexyl)phenyl]methanone)

((4,5-dichloro-1H-pyrrol-2-yl)-[2,4-dihydroxy-3-((S)-4-methylhexyl)phenyl]methanone)

C18H21Cl2NO3 (369.0898)


   

(3R)-3-(5,8-dihydroxy-6-methoxy-2-methyl-4-oxo-4H-naphtho[2,3-b]pyran-10-yl)pyrrolidine-2,5-dione|(R)-10-(3-succinimidyl)-TMC-256A1

(3R)-3-(5,8-dihydroxy-6-methoxy-2-methyl-4-oxo-4H-naphtho[2,3-b]pyran-10-yl)pyrrolidine-2,5-dione|(R)-10-(3-succinimidyl)-TMC-256A1

C19H15NO7 (369.0848)


   

Drahebephin B

Drahebephin B

C19H15NO7 (369.0848)


   

Lycoramine HBr

(1R,12S,14S)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9-trien-14-ol;hydrobromide

C17H24BrNO3 (369.0939)


   

2H-1-Benzopyran-2-one, 4,8-dihydroxy-3-[(1S)-1-(4-nitrophenyl)-3-oxobutyl]- (Acenocoumarol metaboli

2H-1-Benzopyran-2-one, 4,8-dihydroxy-3-[(1S)-1-(4-nitrophenyl)-3-oxobutyl]- (Acenocoumarol metaboli

C19H15NO7 (369.0848)


   

2H-1-Benzopyran-2-one, 4,7-dihydroxy-3-[(1S)-1-(4-nitrophenyl)-3-oxobutyl]- (Acenocoumarol metabolit

2H-1-Benzopyran-2-one, 4,7-dihydroxy-3-[(1S)-1-(4-nitrophenyl)-3-oxobutyl]- (Acenocoumarol metabolit

C19H15NO7 (369.0848)


   

Homapin

3-[(2-hydroxy-2-phenylacetyl)oxy]-8,8-dimethyl-8-azabicyclo[3.2.1]octan-8-ium bromide

C17H24BrNO3 (369.0939)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03B - Belladonna and derivatives, plain > A03BB - Belladonna alkaloids, semisynthetic, quaternary ammonium compounds Homatropine methylbromide (Homatropine methobromide) is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC50 of 162.5 nM and 170.3 nM, respectively.

   

Normonal

N-[(1R,2S,6R)-4-azatricyclo[5.2.1.0^{2,6}]decan-4-yl]-4-chloro-3-sulfamoylbenzene-1-carboximidic acid

C16H20ClN3O3S (369.0914)


D045283 - Natriuretic Agents > D004232 - Diuretics > D049994 - Sodium Potassium Chloride Symporter Inhibitors D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators

   

10-Methyl-9-phenylacridinium perchlorate

10-Methyl-9-phenylacridinium perchlorate

C20H16ClNO4 (369.0768)


   

Gallium,tris(2,4-pentanedionato-kO,kO)-, (OC-6-11)- (9CI)

Gallium,tris(2,4-pentanedionato-kO,kO)-, (OC-6-11)- (9CI)

C15H24GaO6 (369.0829)


   

Disperse Yellow Se-Fl

Disperse Yellow Se-Fl

C18H15N3O4S (369.0783)


   

3-METHYLCYTIDINE METHOSULFATE

3-METHYLCYTIDINE METHOSULFATE

C11H19N3O9S (369.0842)


   

Lansoprazole Sulfide N-Oxide

Lansoprazole Sulfide N-Oxide

C16H14F3N3O2S (369.0759)


   

5-azido-1,3-dimethyl-6-nitro-8-phenylpyrido[2,3-d]pyrimidine-2,4,7-trione

5-azido-1,3-dimethyl-6-nitro-8-phenylpyrido[2,3-d]pyrimidine-2,4,7-trione

C15H11N7O5 (369.0822)


   

N-[6-(1H-indazol-5-yl)naphthalen-2-yl]thiophene-2-carboxamide

N-[6-(1H-indazol-5-yl)naphthalen-2-yl]thiophene-2-carboxamide

C22H15N3OS (369.0936)


   

N-[6-(1H-indazol-4-yl)naphthalen-2-yl]thiophene-3-carboxamide

N-[6-(1H-indazol-4-yl)naphthalen-2-yl]thiophene-3-carboxamide

C22H15N3OS (369.0936)


   

N-[6-(1H-indazol-5-yl)naphthalen-2-yl]thiophene-3-carboxamide

N-[6-(1H-indazol-5-yl)naphthalen-2-yl]thiophene-3-carboxamide

C22H15N3OS (369.0936)


   

Thiazolidine, 2-(4-methylphenyl)-3-(1-naphthalenylsulfonyl)- (9CI)

Thiazolidine, 2-(4-methylphenyl)-3-(1-naphthalenylsulfonyl)- (9CI)

C20H19NO2S2 (369.0857)


   

Thiazolidine, 2-(4-methylphenyl)-3-(2-naphthalenylsulfonyl)- (9CI)

Thiazolidine, 2-(4-methylphenyl)-3-(2-naphthalenylsulfonyl)- (9CI)

C20H19NO2S2 (369.0857)


   
   

Hyoscyamine Hydrobromide

Hyoscyamine Hydrobromide

C17H24BrNO3 (369.0939)


   

Tetraethylenepentamine Pentahydrochloride

Tetraethylenepentamine Pentahydrochloride

C8H28Cl5N5 (369.0787)


   

3-(Methylsulfonyl)-L-phenylalanine phenylmethyl ester hydrochloride

3-(Methylsulfonyl)-L-phenylalanine phenylmethyl ester hydrochloride

C17H20ClNO4S (369.0802)


   

tert-butyl 4-[(4-bromophenyl)methoxy]piperidine-1-carboxylate

tert-butyl 4-[(4-bromophenyl)methoxy]piperidine-1-carboxylate

C17H24BrNO3 (369.0939)


   

Dexlansoprazole

Dexlansoprazole

C16H14F3N3O2S (369.0759)


A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

   
   
   

N-(4-(5-((1H-Benzimidazol-2-ylamino)methyl)-2-thienyl)-1,3-thiazol-2-YL)guanidine

N-(4-(5-((1H-Benzimidazol-2-ylamino)methyl)-2-thienyl)-1,3-thiazol-2-YL)guanidine

C16H15N7S2 (369.083)


   

Homatropine Methylbromide

Homatropine Methylbromide

C17H24BrNO3 (369.0939)


A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03B - Belladonna and derivatives, plain > A03BB - Belladonna alkaloids, semisynthetic, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Homatropine methylbromide (Homatropine methobromide) is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC50 of 162.5 nM and 170.3 nM, respectively.

   

Tripamide

Tripamide

C16H20ClN3O3S (369.0914)


D045283 - Natriuretic Agents > D004232 - Diuretics > D049994 - Sodium Potassium Chloride Symporter Inhibitors D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic D049990 - Membrane Transport Modulators

   

2-[(5-butyl-1H-1,2,4-triazol-3-yl)thio]-N-(4-sulfamoylphenyl)acetamide

2-[(5-butyl-1H-1,2,4-triazol-3-yl)thio]-N-(4-sulfamoylphenyl)acetamide

C14H19N5O3S2 (369.0929)


   

2-[[1-oxo-2-[[5-(3-pyridinyl)-1H-1,2,4-triazol-3-yl]thio]ethyl]amino]benzoic acid methyl ester

2-[[1-oxo-2-[[5-(3-pyridinyl)-1H-1,2,4-triazol-3-yl]thio]ethyl]amino]benzoic acid methyl ester

C17H15N5O3S (369.0896)


   

(E)-3-[5-(4-Acetyl-phenyl)-furan-2-yl]-2-(5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-acrylic acid

(E)-3-[5-(4-Acetyl-phenyl)-furan-2-yl]-2-(5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-acrylic acid

C18H15N3O4S (369.0783)


   

Isopropyl (3-oxo-1-{[(2-thienylcarbonyl)amino]carbonothioyl}-2-piperazinyl)acetate

Isopropyl (3-oxo-1-{[(2-thienylcarbonyl)amino]carbonothioyl}-2-piperazinyl)acetate

C15H19N3O4S2 (369.0817)


   

N4-(4-Fluorophenyl)-N5-(2-nitrophenyl)-1H-imidazole-4,5-dicarboxamide

N4-(4-Fluorophenyl)-N5-(2-nitrophenyl)-1H-imidazole-4,5-dicarboxamide

C17H12FN5O4 (369.0873)


   

5-[(2-Chlorophenyl)methylamino]-2-(3,4-dimethoxyphenyl)-4-oxazolecarbonitrile

5-[(2-Chlorophenyl)methylamino]-2-(3,4-dimethoxyphenyl)-4-oxazolecarbonitrile

C19H16ClN3O3 (369.088)


   

didemethylasterriquinone D(1-)

didemethylasterriquinone D(1-)

C22H13N2O4- (369.0875)


   
   

6-Hydroxy-R-acenocoumarol

6-Hydroxy-R-acenocoumarol

C19H15NO7 (369.0848)


   

(S)-7-Hydroxyacecoumarol

(S)-7-Hydroxyacecoumarol

C19H15NO7 (369.0848)


   

8-Hydroxy-R-acenocoumarol

8-Hydroxy-R-acenocoumarol

C19H15NO7 (369.0848)


   
   
   

MMPIP (hydrochloride)

MMPIP (hydrochloride)

C19H16ClN3O3 (369.088)


MMPIP hydrochloride is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP hydrochloride acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP hydrochloride alleviates pain and normalizes affective and cognitive behavior in neuropathic mice[1][2].

   

3-{4,5-dihydroxy-6-methoxy-2-methyl-8-oxocyclohexa[g]chromen-10-yl}-5-hydroxy-3,4-dihydropyrrol-2-one

3-{4,5-dihydroxy-6-methoxy-2-methyl-8-oxocyclohexa[g]chromen-10-yl}-5-hydroxy-3,4-dihydropyrrol-2-one

C19H15NO7 (369.0848)


   

n-{2-[(5-hydroxy-7-methoxy-2-methyl-4-oxochromen-6-yl)methanesulfonyl]ethyl}ethanimidic acid

n-{2-[(5-hydroxy-7-methoxy-2-methyl-4-oxochromen-6-yl)methanesulfonyl]ethyl}ethanimidic acid

C16H19NO7S (369.0882)


   

methyl 4-(3-acetyl-1,5-dihydroxyisoquinolin-4-yl)-3,5-dihydroxybenzoate

methyl 4-(3-acetyl-1,5-dihydroxyisoquinolin-4-yl)-3,5-dihydroxybenzoate

C19H15NO7 (369.0848)


   

(3r)-3-{4,5-dihydroxy-6-methoxy-2-methyl-8-oxocyclohexa[g]chromen-10-yl}-5-hydroxy-3,4-dihydropyrrol-2-one

(3r)-3-{4,5-dihydroxy-6-methoxy-2-methyl-8-oxocyclohexa[g]chromen-10-yl}-5-hydroxy-3,4-dihydropyrrol-2-one

C19H15NO7 (369.0848)